Trump’s Drug Price Initiative Has No Impact On Most US Patients’ CostsBy Press Room5 October 2025 At a news conference this week, President Trump touted a deal with Pfizer in which the drug company will sell…
Drug Makers And Payers To Blame For Biosimilar Barriers In U.S. MarketBy Press Room4 September 2025 If there is one thing that all stakeholders in the prescription drug supply chain can agree on it’s that patients’…
Pharmacy Benefit Manager Reform: Lots Of Talk But Little ActionBy Press Room15 March 2024 At yesterday’s Senate Finance Committee hearing, Chair Ron Wyden, D-Oregon, and Ranking Member Mike Crapo, R-Idaho, urged their colleagues to…